Society for Clinical Research Sites Welcomes Clinical Ink as New Global Impact Partner
SCRS announced a two-year collaboration with Clinical Ink
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Clinical Ink, the pioneering provider of eSource solutions for clinical trials. Clinical Ink will participate as a Global Impact Partner (GIP) and align with other sponsors, CROs and service providers who share an ongoing commitment to research site success.
“Clinical Ink’s relationship with SCRS illustrates their commitment to strengthening site partnerships and accelerating collaboration amongst industry stakeholders,” comments Christine Pierre, SCRS President. “Working together with this leading organization is a significant strategic development for SCRS, and will add considerable momentum to our Global Impact Partnership program. SCRS is proud to welcome Clinical Ink to our community.”
“This partnership reinforces our commitment to sites and dedication to making clinical research easier for sites, sponsors, subjects and regulators,” said Ed Seguine, CEO, Clinical Ink. “Clinical Ink was co-founded by a clinical investigator who understood the challenges of clinical research from 20+ years of experience. Through new collaborations as an SCRS GIP, we look forward to gaining insights that will help guide the continued evolution of SureSource as a primary tool for sites.”
As a Global Impact Partner (GIP), Clinical Ink will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
